منابع مشابه
Conditional and Sequential Approval Voting on Combinatorial Domains
Several methods exist for making collective decisions on a set of variables when voters possibly have preferential dependencies. None is based on approval voting. We define a family of rules for approval-based voting on combinatorial domains, where voters cast conditional approval ballots, allowing them to approve values of a variable conditionally on the values of other variables. We study thr...
متن کاملSunitinib Induced Immune Thrombocytopenia
Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ systems including hematologic system. Although the neutropenia and thrombocytopenia commonly happens as Gra...
متن کاملConditional Approval Pathways: The “Special” Case of Global Regenerative Medicine Regulation
B iomedical innovation and the societal benefits it catalyses is essential and challenging. Yet from reductionist viewpoint, the term innovation has been consistently misapplied to describe the process of translating scientific advancements from the laboratory to patient bedside. It is easy to forget that etymologically, innovation stems from Latin roots meaning to change or develop and introdu...
متن کاملApproval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
PURPOSE To describe the Food and Drug Administration (FDA) review and approval of sunitinib malate (Sutent). Sunitinib received regular approval for the treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to imatinib mesylate (Gleevec). Additionally, sunitinib received accelerated approval for the treatment of advanced renal cell carcinoma. EXPERIMENTAL...
متن کاملFDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
On May 20, 2011, the U.S. Food and Drug Administration (FDA) approved sunitinib malate capsules (Sutent®; Pfizer, Inc., New York) for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) in patients with unresectable locally advanced or metastatic disease. In a phase III randomized trial, 171 patients received either sunitinib (37.5 mg) or placebo once dail...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Supplements
سال: 2007
ISSN: 1359-6349
DOI: 10.1016/j.ejcsup.2007.09.041